Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
NCT ID: NCT02353897
Last Updated: 2020-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2014-10-31
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient who has prior to and independent of the study decided to undergo long term treatment of GL only (at least three cycles).
* Patient able to comply with the protocol (completion of web questionnaires).
* Patient whom physician intended to treat with Dysport independent of participation in the study.
Exclusion Criteria
* Participation in an interventional trial within 30 days prior to study entry.
* Patient who is at risk in terms of precautions, warnings, and contraindication (follow local Summary of Product Characteristics (SmPC) of Dysport).
* Female patient who is pregnant, nursing or planning a pregnancy during the study.
* Hypersensitivity to Dysport® or to its excipients.
* Presence of infection at the proposed injection sites.
* Presence of myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral sclerosis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ERASE
Malvern, , Australia
SouthDerm
Sydney, , Australia
Clinica Laura Bariquelo Buratini
Botucatu, , Brazil
Estetická Dermatologie
Brno, , Czechia
BcD Clinic s.r.o.
Prague, , Czechia
Laser Center DARUS
Almaty, , Kazakhstan
Dr Haddad Clinics
Beirut, , Lebanon
Centre of Aesthetic Medicine "Chistie prudi"
Moscow, , Russia
Preventive Medicine Clinic "Vallex M"
Moscow, , Russia
Plastic Surgery Institute
Moscow, , Russia
FI IF & TC & apos; Eye microsurgery & apos
Novosibirsk, , Russia
Clinic of Aesthetic Medicine
Saint Petersburg, , Russia
Kocaeli University School of Medecine Umuttepe
Kocaeli, , Turkey (Türkiye)
Clinic of Aesthetic medicine "Ankor"
Kyiv, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gubanova E, Haddad Tabet M, Bergerova Y, Moiseieva O, Chemeris A, Sanches E, Sharova A, Rodriguez Pose L, Raymond R, Prygova I, Carlisle I. Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport(R)/Azzalure(R)): Primary Results of the APPEAL Noninterventional Study. Aesthetic Plast Surg. 2018 Dec;42(6):1672-1680. doi: 10.1007/s00266-018-1200-4. Epub 2018 Aug 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Y-79-52120-201
Identifier Type: -
Identifier Source: org_study_id